Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransCode Therapeutics ( (RNAZ) ) has shared an announcement.
At the 2025 Annual Meeting of Stockholders held on August 29, 2025, TransCode Therapeutics, Inc. successfully passed all proposals, including the election of four directors and the approval of an amendment to increase shares in their Stock Option and Incentive Plan. Additionally, the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for 2025 was ratified, and the adjournment proposal was approved, although not needed due to sufficient votes for the stock plan amendment.
The most recent analyst rating on (RNAZ) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics, Inc. operates in the biotechnology industry, focusing on developing RNA-targeted therapeutics for cancer treatment. The company aims to address unmet medical needs in oncology through its innovative therapeutic solutions.
Average Trading Volume: 97,194
Technical Sentiment Signal: Sell
Current Market Cap: $8.11M
See more insights into RNAZ stock on TipRanks’ Stock Analysis page.